Table 2. PD-1/PD-L1 expression and patient characteristics.
| Characteristic | PD-1+(no/%) | PD-1–(no/%) | P-value | Median PD-1 levels | PD-L1+(no/%) | PD-L1–(no/%) | P-value | Median PD-L1 levels |
|---|---|---|---|---|---|---|---|---|
|
Gender | ||||||||
| Male | 24/55.8 | 41/51.9 | 0.68 | 60 | 36/52.9 | 30/54.5 | 0.86 | 60 |
| Female | 19/44.2 | 38/48.1 | 20 | 32/47.1 | 25/45.5 | 80 | ||
|
Smoking history | ||||||||
| Never/former smokers | 27/73.0 | 65/90.3 | 0.02 | 20 | 53/86.9 | 41/82.0 | 0.48 | 60 |
| Current smokers | 10/27.0 | 7/9.7 | 60 | 8/13.1 | 9/18.0 | 30 | ||
|
Histology | ||||||||
| Adenocarcinoma | 29/85.3 | 52/75.4 | 0.25 | 40 | 52/88.1 | 30/65.2 | 0.005 | 100 |
| Squamous-cell carcinoma | 5/14.7 | 17/24.6 | 0 | 7/11.9 | 16/34.8 | 0 | ||
|
EGFR
status | ||||||||
| EGFR mutated | 17/39.5 | 38/48.1 | 0.36 | 20 | 40/58.8 | 16/29.1 | 0.001 | 120 |
| EGFR wild type | 26/60.5 | 41/51.9 | 40 | 28/41.2 | 39/70.9 | 20 | ||
|
KRAS
status | ||||||||
| KRAS mutated | 16/37.2 | 12/15.2 | 0.006 | 60 | 15/22.1 | 13/23.6 | 0.84 | 55 |
| KRAS wild type | 27/62.8 | 67/84.8 | 25 | 53/77.9 | 42/76.4 | 80 | ||
|
ALK
status | ||||||||
| ALK translocated | 3/7.0 | 7/8.9 | 1.00 | 15 | 6/8.8 | 4/7.3 | 1.00 | 115 |
| ALK wild type | 40/93.0 | 72/91.1 | 35 | 62/91.2 | 51/92.7 | 70 | ||
|
EGFR
statusa | ||||||||
| EGFR mutated | 17/70.8 | 38/63.3 | 0.51 | 20 | 40/85.1 | 16/42.1 | <0.001 | 120 |
| Triple negativeb | 7/29.2 | 22/36.7 | 40 | 7/14.9 | 22/57.9 | 20 | ||
|
KRAS
statusa | ||||||||
| KRAS mutated | 16/69.6 | 12/35.3 | 0.01 | 60 | 15/68.2 | 13/37.1 | 0.02 | 55 |
| Triple negativeb | 7/30.4 | 22/64.7 | 40 | 7/31.8 | 22/62.9 | 20 | ||
|
ALK
statusa | ||||||||
| ALK translocated | 3/30.0 | 7/24.1 | 0.70 | 15 | 6/46.2 | 4/15.4 | 0.06 | 115 |
| Triple negativeb | 7/70.0 | 22/75.9 | 40 | 7/53.8 | 22/84.6 | 20 | ||
Abbreviations: ALK= anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor; KRAS=Kirsten rat sarcoma viral oncogene homologue; PD-1=programmed death-1; PD-L1=programmed death-ligand 1; PD-1+=PD-1 positive; PD-1–=PD-1 negative; PD-L1+=PD-L1 positive; PD-L1–=PD-L1 negative.
a
Analysis performed vs triple negative cases.
b
Triple negative included EGFR/KRAS/ALK wild-type patients.